Close Menu

NEW YORK – A combined method measuring both circulating tumor DNA and circulating tumor cells can detect lingering residual disease in women with triple-negative breast cancer after neoadjuvant chemotherapy and predicts disease recurrence, according to a new study.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.